A BILL 
To amend the Public Health Service Act to provide for 
the publication of a list of licensed biological products, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Purple Book Con-
4
tinuity Act of 2019’’. 
5
SEC. 2. PUBLIC LISTING. 
6
Section 351(k) of the Public Health Service Act (42 
7
U.S.C. 262(k)) is amended by adding at the end the fol-
8
lowing: 
9
‘‘(9) PUBLIC LISTING.— 
10
04:04 Mar 19, 2019
H1520
2 
•HR 1520 IH
‘‘(A) IN GENERAL.— 
1
‘‘(i) INITIAL PUBLICATION.—Not later 
2
than 60 days after the date of enactment 
3
of the Purple Book Continuity Act of 
4
2019, the Secretary shall publish and 
5
make available to the public electroni-
6
cally— 
7
‘‘(I) a list in alphabetical order of 
8
the official and proprietary name of 
9
each biological product for which a 
10
biologics license under subsection (a) 
11
or this subsection is in effect as of 
12
such date of enactment; 
13
‘‘(II) the date of licensing if the 
14
biological product is licensed after 
15
1981 and the number of the applica-
16
tion which was approved; and 
17
‘‘(III) whether in vitro or in vivo 
18
bioequivalence studies, or both such 
19
studies, are required for applications 
20
filed under this subsection which will 
21
refer to the biological product pub-
22
lished. 
23
‘‘(ii) 
REVISIONS.—Every 
30 
days 
24
after the publication of the first list under 
25
04:04 Mar 19, 2019
H1520
3 
•HR 1520 IH
clause (i), the Secretary shall revise the list 
1
to include each biological product which 
2
has been licensed under subsection (a) or 
3
this subsection during the 30-day period. 
4
‘‘(iii) PATENT
INFORMATION.—When 
5
patent information has been provided by 
6
the reference product sponsor to the sub-
7
section (k) applicant respecting a biological 
8
product included on the list published 
9
under this subparagraph, the Secretary 
10
shall, in revisions made under clause (ii), 
11
include such information for such biologi-
12
cal product. 
13
‘‘(B) DATE OF PUBLICATION.—A biological 
14
product for which a license is in effect under 
15
subsection (a) or this subsection shall, for pur-
16
poses of this subsection, be considered to have 
17
been published under subparagraph (A) on the 
18
later of— 
19
‘‘(i) the date of its licensing; or 
20
‘‘(ii) the date of its publication in the 
21
list that— 
22
‘‘(I) was published under this 
23
section before the initial publication of 
24
the list under subparagraph (A); and 
25
04:04 Mar 19, 2019
H1520
4 
•HR 1520 IH
‘‘(II) was equivalent to the list 
1
published under section 505(j)(7) of 
2
the Federal Food, Drug, and Cos-
3
metic Act and comprised of patents 
4
associated 
with 
applications 
filed 
5
under subsection (a) of this section or 
6
under this subsection. 
7
‘‘(C) WITHDRAWAL OR SUSPENSION OF LI-
8
CENSURE.—If the licensing of a biological prod-
9
uct was withdrawn or suspended for safety, pu-
10
rity, or potency reasons, it may not be pub-
11
lished in the list under subparagraph (A). If the 
12
withdrawal or suspension occurred after its 
13
publication in such list— 
14
‘‘(i) it shall be immediately removed 
15
from such list— 
16
‘‘(I) for the same period as the 
17
withdrawal or suspension; or 
18
‘‘(II) if the listed drug has been 
19
withdrawn from sale, for the period of 
20
withdrawal from sale or, if earlier, the 
21
period ending on the date the Sec-
22
retary determines that the withdrawal 
23
from sale is not for safety, purity, or 
24
potency reasons; and 
25
04:04 Mar 19, 2019
H1520
5 
•HR 1520 IH
‘‘(ii) a notice of the removal shall be 
1
published in the Federal Register.’’. 
2
SEC. 3. REVIEW AND REPORT ON TYPES OF BIOLOGICAL 
3
PRODUCT PATENTS TO BE LISTED. 
4
Not later than 3 years after the date of enactment 
5
of this Act, the Secretary of Health and Human Services 
6
shall— 
7
(1) complete a review of, and formulate rec-
8
ommendations on, the types of biological product 
9
patents that should be included in or removed from 
10
the list required by paragraph (9) of section 351(k) 
11
of the Public Health Service Act (42 U.S.C. 262(k)), 
12
as added by section 2; and 
13
(2) report such recommendations to the Con-
14
gress. 
15
Æ 
04:04 Mar 19, 2019
H1520
